Abstract Number: 658 • 2019 ACR/ARP Annual Meeting
Disentangling Connective Tissue Diseases: Overlaps and Disparities in Clinical Diagnosis, Classification Criteria and Autoantibodies – Results from the Lupus Extended Autoimmune Phenotype Study
Background/Purpose: Connective tissue diseases (CTDs) are a heterogeneous group of diseases with overlapping clinical features and shared immunopathology. In routine practice, a clinician diagnosis is…Abstract Number: 897 • 2019 ACR/ARP Annual Meeting
Mortality Rates After Coronary Revascularization Procedures Among Systemic Lupus Erythematosus Compared to Diabetes Mellitus and General Population Medicaid Patients
Background/Purpose: Despite similar myocardial infarction risks in SLE and diabetes mellitus (DM) patients, individuals with SLE enrolled in Medicaid had substantially higher rates of coronary…Abstract Number: 1571 • 2019 ACR/ARP Annual Meeting
Validity Evidence Supports the Use of Automated Neuropsychological Assessment Metrics (ANAM) as a Screening Tool for Cognitive Impairment in Patients with Systemic Lupus Erythematosus
Background/Purpose: Cognitive impairment (CI) is highly prevalent in Systemic Lupus Erythematosus (SLE). Screening for CI in SLE may be delayed, if relying on the American…Abstract Number: 1844 • 2019 ACR/ARP Annual Meeting
The Contribution of Disease Activity, Depression, and Anxiety to Health-Related and Non-Health-Related Quality of Life in US and Filipino Patients with SLE
Background/Purpose: It is well known that patients with SLE are often afflicted with deficits in quality of life and problems with physical impairment and psychosocial…Abstract Number: 2549 • 2019 ACR/ARP Annual Meeting
Population Pharmacokinetics of Atacicept in Systemic Lupus Erythematosus (SLE) – an Analysis of Three Clinical Trials
Background/Purpose: Atacicept targets the B-cell stimulating factors BLyS and APRIL and has been shown to reduce SLE disease activity. The aim of the analysis was…Abstract Number: 662 • 2019 ACR/ARP Annual Meeting
Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus
Background/Purpose: Patient Reported Outcomes (PROs) can provide important data about the impact of a disease on an individual and/or the quality of the response to…Abstract Number: 942 • 2019 ACR/ARP Annual Meeting
A Randomized Prospective Trial to Assess the Clinical Utility of Multianalyte Assay with Complement Activation Products in Diagnosing Systemic Lupus Erythematosus
Background/Purpose: Cell-Bound Complement Activation Products (CB-CAPs) in multianalyte assay panel (MAP) is a diagnostic immunology laboratory test with established clinical validity in distinguishing systemic lupus…Abstract Number: 1574 • 2019 ACR/ARP Annual Meeting
Causes of Death in SLE: Analysis of Inpatient Death from 2000-2018 in a Tertiary Care Hospital in India
Background/Purpose: Mortality in Systemic lupus erythematosus (SLE) has reduced over the years but it is still two to three folds as compared to general population.…Abstract Number: 1864 • 2019 ACR/ARP Annual Meeting
Gaps in Care for Patients with SLE: Data from the ACR’s RISE Registry
Background/Purpose: Although multiple national quality measures focus on the management and safety of rheumatoid arthritis, few measures address the care of patients with SLE. We…Abstract Number: 2555 • 2019 ACR/ARP Annual Meeting
Antimalarial-Induced Cardiomyopathy: Outcome in 10 Patients
Background/Purpose: Antimalarial-induced cardiomyopathy (AMIC) is a hypertrophic cardiomyopathy with conduction system disorders, cardiac biomarker abnormalities and a short-term mortality of 45%. Data on the reversibility…Abstract Number: 667 • 2019 ACR/ARP Annual Meeting
The PROMIS-29 as a Measure of Type 1 and 2 SLE Activity
Background/Purpose: We have developed a new conceptual model that characterizes lupus into subtypes based on physician- and patient-reported measures: Type 1 is assessed by the…Abstract Number: 975 • 2019 ACR/ARP Annual Meeting
Functional Impairment of Mitf and the MiT Transcription Factor Family Dysregulates B Cell Activation and Function
Background/Purpose: Autoreactive B cells are central in the development of many autoimmune diseases, such as systemic lupus erythematosus (SLE), and are normally eliminated or inactivated…Abstract Number: 1575 • 2019 ACR/ARP Annual Meeting
Lymphocyturia Is a Good and Cheap Biomarker for Active Lupus Nephritis and Is Sensitive to Change
Background/Purpose: Multiple urinary biomarkers have been described for lupus nephritis, however none has reached the clinic due to either complex methodology or low discriminatory power.…Abstract Number: 1941 • 2019 ACR/ARP Annual Meeting
Interactions Between Genome-Wide Genetic Factors and Current Smoking in Determining SLE Risk
Background/Purpose: We have previously reported that current smoking (or having recently quit within 4 years) was associated with elevated risk of SLE, in particular anti-dsDNA+…Abstract Number: 2577 • 2019 ACR/ARP Annual Meeting
SLE Disease Activity May Be Associated with Choroidal Thickness
Background/Purpose: SLE is an autoimmune disease with widespread organ involvement. High disease activity has previously been associated with higher risk of organ damage and mortality.…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 38
- Next Page »